Mucinous tumors of the pancreas are rare and the diagnosis of invasive carcinoma can be a dilemma. While metastatic disease from mucinous cystadenocarcinoma (MCAC) and invasive intraductal papillary mucinous neoplasms (IPMN) have been reported, no extraperitoneal mucinous cystic metastatic disease has been described. When metastatic, the overall survival rates for invasive adenocarcinoma, mucinous cystadenocarcinoma (MCAC) and invasive intraductal papillary mucinous neoplasms (IPMN) are similar. The best improvement in the overall and progression free survival has been demonstrated with FOLFIRINOX (folinic acid -fluorouracil -irinotecan -oxaliplatin) for metastatic adenocarcinoma and Gemcitabine based regimens for MCAC. However, the variable responses of metastatic mucinous lesions have been observed and the overall prognosis remains poor. We describe a case of a patient who presented with metastatic adenocarcinoma of the pancreas as cystic masses in the supraclavicular and axillary regions. Additionally, this patient was initially treated with FOLFIRINOX and continues to have stable primary and metastatic disease after 18 months from the diagnosis. 
INTRODUCTION
Patients with unresectable pancreatic cancer continue to experience poor overall survival. While metastatic adenocarcinoma to various sites of the body is well documented, metastatic disease presenting as mucinous cystic lesions have primarily been reported as mucinous cystadenocarcinoma (MCAC) and invasive intraductal papillary mucinous neoplasms (IPMN) and include only intraperitoneal locations. [1] [2] [3] [4] [5] [6] Both metastatic adenocarcinoma as well as metastatic MCAC, when treated with systemic chemotherapy only, have an overall survival of approximately 11 months. 7, 8 Metastatic adenocarcinoma when compared to invasive metastatic IPMN have also been proven to have a similar overall survival. 6 We report a case of a patient with metastatic adenocarcinoma of the pancreas that presented initially with metastatic mucinous cystic lesions to the axilla and supraclavicular region and (Fig. 3 ). An endoscopic ultrasound was performed that showed a round, cystic mass in the pancreatic body that measured at 46 mm with a hypoechoic small solid/cystic component that was 15×20 mm in size (Fig. 4) . The mass measured at 5×4. Currently, FOLFIRINOX has been most effective for metastatic pancreatic cancer with a median overall survival of 11 months. 8 When invasive MCAC were found to be metastatic, overall survival is comparable to metastatic adenocarcinoma. 6 Patients with resectable MCAC have reported 5-year overall survival rates as high as 62-63%.
11,12
For patients treated neoadjuvantly or non-operatively, systemic chemotherapy regimens included Gemcitabine alone or in combination with Oxaliplatin with variable responses.
Favorable responses were observed, however, with 5FU
and radiation, but primarily in the neoadjuvant setting. 13, 14 MCAC patients that were treated with systemic chemotherapy alone had a survival rate of 12% at 2 years, which ranged from 4-37 months and had a median of 10.5-11 months. 7, 12, 15, 16 Given the poor prognosis for both metastatic adenocarcinoma as well as MCAC/IPMN, the decision was made to treat our patient with FOLFIRINOX. 8 Our patient continues to have a stable disease (at the primary and metastatic sites) at approximately 18 months from her initial diagnosis.
In conclusion, this is the first report of a pancreatic adenocarcinoma that presented as a metastatic cystic lesion to the axillary and supraclavicular regions. She was originally treated with FOLFIRINOX and continues to have stable primary and metastatic disease.
